UroGen Pharma (FRA:UR8) Growth Rank : 3 (As of Jun. 08, 2024)

View and export this data going back to 2018. Start your Free Trial

What is UroGen Pharma Growth Rank?

UroGen Pharma has the Growth Rank of 3.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Competitive Comparison of UroGen Pharma's Growth Rank

For the Biotechnology subindustry, UroGen Pharma's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UroGen Pharma's Growth Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's Growth Rank distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's Growth Rank falls into.

UroGen Pharma Growth Rank Related Terms

Thank you for viewing the detailed overview of UroGen Pharma's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

UroGen Pharma (FRA:UR8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (FRA:UR8) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

URGN:USA

Address

400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540

Website

https://www.urogen.com

UroGen Pharma Ltd is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative solutions that treat urothelial and specialty cancers. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.

UroGen Pharma (FRA:UR8) Headlines

No Headlines